Iterative Health Partners with Gastroenterology Associates of New Jersey to Expand Access to Advanced GI Research
Iterative Health, a healthcare technology and clinical research services company focused on accelerating medical innovation, has announced a strategic partnership with Gastroenterology Associates of New Jersey (GANJ) to expand access to advanced gastrointestinal (GI) clinical research across New Jersey. The collaboration is designed to integrate research directly into community-based gastroenterology practices, allowing more patients to participate in clinical trials while receiving care from their trusted local physicians.
The partnership represents a significant step toward decentralizing clinical research by bringing innovative therapies closer to patients rather than limiting participation to large academic medical centers. Through the agreement, Iterative Health will become GANJ’s dedicated clinical research partner, establishing new research infrastructure within the practice while leveraging its operational expertise, technology platforms, and extensive sponsor relationships.
By combining GANJ’s large community physician network with Iterative Health’s clinical trial capabilities and artificial intelligence-driven research solutions, both organizations aim to increase patient access to investigational treatments, improve trial efficiency, and generate more representative clinical data that reflects real-world patient populations.
Bringing Clinical Research Into Community Gastroenterology Practices
Clinical research has traditionally been concentrated at academic hospitals and major research institutions, making participation difficult for many patients due to travel requirements, scheduling challenges, and limited geographic access.
The partnership between Iterative Health and Gastroenterology Associates of New Jersey seeks to overcome these barriers by embedding research opportunities directly within routine gastroenterology care.
As part of the collaboration, two newly established research centers have opened in Toms River and Clifton, New Jersey, becoming part of Iterative Health’s expanding global research network of more than 110 clinical research sites.
The companies are also actively evaluating opportunities to establish additional research sites across GANJ’s broader provider network, allowing more patients throughout the state to access clinical studies without leaving their local communities.
Embedding research into community practices enables physicians to identify eligible patients during regular clinical visits while offering seamless enrollment into trials evaluating next-generation gastrointestinal therapies.
Expanding Research Opportunities Across New Jersey
New Jersey represents an ideal environment for expanding community-based clinical research due to its unique geographic and demographic characteristics.
Located between the major academic medical centers of New York City and Philadelphia, the state serves a large and diverse patient population while maintaining strong healthcare infrastructure.
With a population exceeding 9.5 million residents, New Jersey is among the most densely populated states in the United States, providing researchers with access to substantial numbers of patients across a wide range of gastrointestinal conditions.
The state’s racial and ethnic diversity also exceeds national averages, creating opportunities to enroll more representative patient populations in clinical trials.
Improving diversity in clinical research has become an increasingly important objective throughout the pharmaceutical and healthcare industries, as broader participation helps ensure that study findings better reflect the patients who will ultimately receive approved therapies.
By conducting research within community practices, investigators can reach populations that have historically been underrepresented in clinical studies.
Leveraging an Extensive Community Care Network
Gastroenterology Associates of New Jersey has built one of the state’s largest gastroenterology practice networks.
The organization operates 28 clinical locations across New Jersey, providing digestive health services to thousands of patients annually.
Its network includes more than 60 healthcare professionals, encompassing gastroenterologists, advanced practice providers, nurses, and clinical specialists dedicated to diagnosing and managing a broad spectrum of gastrointestinal diseases.
By integrating research into this established care network, patients who already receive treatment through GANJ can gain access to clinical trials without needing referrals to distant academic research centers.
This model not only increases convenience but also enables treating physicians to remain actively involved throughout both routine care and clinical research participation.
The approach strengthens continuity of care while reducing logistical barriers that often discourage patient enrollment in research studies.
Combining Clinical Expertise with Research Infrastructure
The partnership combines complementary strengths from both organizations.
GANJ contributes decades of experience delivering specialized gastrointestinal care through an extensive physician network.
Iterative Health provides the operational systems necessary to conduct high-quality clinical research efficiently.
Its capabilities include:
- Clinical trial operations
- Site management services
- Regulatory support
- Patient recruitment strategies
- Sponsor relationships
- Data management
- Artificial intelligence-powered research tools
- Therapeutic expertise across multiple disease areas
Together, these resources create a comprehensive research model capable of supporting pharmaceutical companies, biotechnology firms, medical device developers, and healthcare innovators conducting gastrointestinal clinical studies.
The collaboration is expected to improve study execution while maintaining high standards for patient safety, regulatory compliance, and scientific quality.
Artificial Intelligence Supporting Clinical Research
One distinguishing aspect of Iterative Health’s approach is its use of artificial intelligence to enhance clinical research operations.
AI technologies are increasingly being adopted throughout healthcare to improve efficiency, reduce administrative burden, and support clinical decision-making.
Within clinical research, artificial intelligence can assist with:
- Identifying potentially eligible patients
- Optimizing recruitment
- Predicting enrollment trends
- Streamlining workflow
- Improving protocol adherence
- Enhancing data quality
- Supporting site performance
- Accelerating study timelines
These technologies enable research sites to manage increasingly complex clinical trials while reducing delays that often slow drug development.
By integrating AI-enabled research tools into GANJ’s clinical network, the partnership seeks to improve both operational performance and patient access to investigational therapies.
Supporting Innovation in Inflammatory Bowel Disease
A central focus of the collaboration is inflammatory bowel disease (IBD), one of the most active therapeutic areas within gastroenterology research.
IBD primarily includes:
- Crohn’s disease
- Ulcerative colitis
These chronic autoimmune disorders affect millions of patients worldwide and often require lifelong treatment.
Although numerous therapies are currently available, many patients continue to experience persistent symptoms or lose response to existing medications over time.
Developing new treatment options therefore remains a major priority for researchers, pharmaceutical companies, and healthcare providers.
GANJ recently launched a Comprehensive IBD Care Center, demonstrating its commitment to delivering specialized care for patients living with inflammatory bowel disease.
The new center aligns closely with Iterative Health’s longstanding scientific expertise in IBD clinical development.
By integrating clinical research into the Comprehensive IBD Care Center, eligible patients may gain earlier access to investigational therapies currently being evaluated through clinical trials.
Accelerating Access to Emerging Therapies
Participation in clinical trials provides patients with opportunities to receive promising new treatments before they become widely available.
For patients with chronic gastrointestinal disorders, particularly those who have exhausted standard treatment options, access to investigational therapies may represent an important additional care pathway.
Embedding research within community practices expands these opportunities by reducing many of the obstacles traditionally associated with trial participation.
Instead of traveling long distances to academic hospitals, patients can discuss research participation with physicians they already know and trust.
This community-centered approach may improve enrollment while increasing patient comfort and engagement throughout the research process.
Greater participation also helps sponsors complete studies more efficiently, potentially accelerating regulatory review and future treatment availability.
Strengthening Community-Based Clinical Research
The partnership reflects a broader shift occurring throughout healthcare toward decentralizing clinical research.
Historically, many clinical trials have been conducted primarily at university medical centers.
While these institutions continue to play an essential role in medical innovation, expanding research into community healthcare settings allows studies to include broader patient populations that more closely represent routine clinical practice.
Community-based research also offers several advantages:
- Increased geographic accessibility
- Improved patient diversity
- Greater physician involvement
- Enhanced continuity of care
- Faster patient recruitment
- Better real-world applicability of research findings
These benefits have prompted growing interest among healthcare organizations seeking to integrate research into everyday clinical care.
Leadership Perspective
Dr. George Pavlou, Chief Executive Officer of Gastroenterology Associates of New Jersey, emphasized that the organization’s mission has always centered on providing patients with access to the most advanced gastrointestinal care available.
According to Dr. Pavlou, incorporating clinical research into routine care represents a natural extension of that commitment.
He noted that partnering with Iterative Health provides the operational infrastructure necessary to offer patients access to innovative therapies that have the potential to shape the future of gastrointestinal medicine.
Rather than requiring patients to seek research opportunities elsewhere, the collaboration enables cutting-edge treatments to become available directly within the communities GANJ already serves.
Expanding a National Research Network
The agreement with GANJ continues Iterative Health’s broader strategy of expanding its nationwide community-based research network.
The company has established partnerships with numerous independent physician groups and management services organizations focused on gastrointestinal medicine, hepatology, obesity, and cardiology.
Through these collaborations, Iterative Health has developed one of the largest community-embedded clinical research networks supporting sponsors across the United States.
The organization has also begun expanding internationally, reflecting growing demand for decentralized clinical research models capable of improving patient recruitment and accelerating therapeutic development.
Its research infrastructure supports pharmaceutical and biotechnology companies developing innovative treatments across multiple therapeutic areas while enabling physicians to integrate research into routine patient care.
Building the Future of Gastrointestinal Research
Jonathan Ng, Chief Executive Officer of Iterative Health, said the partnership reflects the company’s long-term strategy of creating the nation’s leading community-based gastrointestinal clinical research network.
He noted that GANJ’s extensive reach across New Jersey strengthens Iterative Health’s ability to connect sponsors with diverse patient populations while expanding research opportunities for physicians and patients alike.
According to Ng, New Jersey’s large, densely populated, and demographically diverse population makes it an important location for conducting high-quality clinical trials capable of generating representative data for future GI therapies.
He emphasized that strengthening community research infrastructure ultimately benefits every stakeholder involved in the clinical development process—from pharmaceutical sponsors and healthcare providers to the patients seeking access to the next generation of gastrointestinal treatments.
Advancing Patient-Centered Research
The partnership between Iterative Health and Gastroenterology Associates of New Jersey highlights the growing importance of integrating clinical research into community healthcare settings. By combining advanced research infrastructure, artificial intelligence-enabled operational support, experienced gastrointestinal specialists, and an extensive network of community practices, the collaboration aims to improve patient access to innovative therapies while accelerating the development of future GI treatments.
As demand for more inclusive, efficient, and patient-centered clinical research continues to grow, partnerships like this are expected to play an increasingly important role in transforming how gastrointestinal studies are conducted. By bringing research closer to where patients already receive care, the initiative has the potential to improve trial participation, generate more representative clinical evidence, and support the continued advancement of gastrointestinal medicine.
Source link: https://www.businesswire.com/
